

Client Update

February 2022 - Interim

Page 1 of 1

Test Name	Test Code	Effective Date
Test Ordering	<u>N/A</u>	<u>N/A</u>
<p>Regulations require that the performing laboratory have a written or electronic request for patient testing from an authorized person to order testing as defined by state law per the Clinical Laboratory Improvement Amendments (“CLIA”). The BRLI test requisition forms are designed to emphasize ordering provider choice and encourage ordering providers to order only those tests, which the ordering provider believes, are appropriate and medically necessary for the diagnosis or treatment of each patient. Providers must clearly document, in the patient’s medical record, his/her intent that a particular test(s) be performed as well as support the medical necessity of the testing to be completed. It is crucial that the ordering provider accurately document their intent for the specific service requested, to support the medical necessity. Services billed to Medicare that are not appropriately documented and medically necessary, will result in recoupment of Medicare payments.</p> <p>If BRLI receives a test order on a non-BRLI test requisition form, an incomplete BRLI test requisition form or a handwritten test order, processing of your test order may be delayed.</p> <p>BRLI has three (3) options available by which an authorized provider may order BRLI testing. They include: 1) manual paper test requisitions; 2) online test ordering via our proprietary electronic ordering system InSightDx; and 3) EMR interface. Online ordering and EMR interface ordering are the more efficient methods of test ordering and help reduce potential human errors in the order creation and entry process. Failure to provide a complete, clear and accurate test requisition may result in a delay in processing of a test order. Without a valid test order, the medical necessity of the code billed is not supported.</p> <p>Handwritten test orders on test requisitions may delay the processing of your test order. Please note that when the laboratory receives a handwritten test order for a “CBC” the laboratory will perform a “CBC w/DIFF, Platelet Ct.”. BRLI is also in the process of updating its test requisition form to include Test Code 0034-9 CBC w/o DIFF (Hemogram)/Plat. Ct. for those ordering providers who do not want a CBC w/DIFF.</p> <p>Test Requisitions will include both test codes 0053-9 CBC w/DIFF, Platelet Ct. and 0034-9 CBC w/o DIFF (Hemogram)/Platelet Ct. Both test codes have been and will continue to be offered through InSightDx and EMR interfaces.</p>		
HER2 Immunohistochemistry	Multiple	February 16,2022
<p>The laboratory will be discontinuing the temporary Breast Cancer HER2 Biomarker Change. Having received sufficient reagents for HER2 IHC (Immunohistochemistry), the previous notification that all HER2 IHC test orders will be converted to HER2 FISH (Fluorescence in-situ Hybridization) is hereby withdrawn.</p>		